Packaging & Serialisation
Packaging turns bulk product into the thing a pharmacist, clinician, or consumer actually receives — and it is where some of GMP's oldest and newest obligations meet. The oldest: labelling control, because a mix-up between two labels is among the most efficient ways a manufacturing operation can hurt someone, which is why 21 CFR 211 devotes specific machinery to label issuance, reconciliation, and line clearance. The container-closure system is itself part of the product's quality argument: it must protect the product for its shelf life, and for sterile products container-closure integrity — evaluated within the framework of USP <1207>, which favours deterministic methods over probabilistic ones — is part of the sterility claim, not an accessory to it.
What this page does not claim
Phases are an organising device, not a regulatory mandate — real programmes overlap them, and a medical device, a food product and a small-molecule drug traverse them differently. Each page says where the differences bite.
What happens in this phase
Packaging turns bulk product into the thing a pharmacist, clinician, or consumer actually receives — and it is where some of GMP's oldest and newest obligations meet. The oldest: labelling control, because a mix-up between two labels is among the most efficient ways a manufacturing operation can hurt someone, which is why 21 CFR 211 devotes specific machinery to label issuance, reconciliation, and line clearance. The container-closure system is itself part of the product's quality argument: it must protect the product for its shelf life, and for sterile products container-closure integrity — evaluated within the framework of USP <1207>, which favours deterministic methods over probabilistic ones — is part of the sterility claim, not an accessory to it.
The newest obligation is identity at the unit level. Serialisation regimes — the US Drug Supply Chain Security Act and the EU's falsified-medicines safety features among them — require a unique identifier on each saleable unit, applied on the line, verified, and exchanged with trading partners so the unit can be traced and verified downstream. The identifier syntax and data carriers ride on GS1 General Specifications, the voluntary standard with effectively mandatory reach because the regulations specify the outcome and GS1 supplies the grammar. Devices carry their own version: unique device identification, embedded in the EU MDR's requirements and in the US regime, ties each device to its record for surveillance and recall precision.
Operationally the phase is a systems phase as much as a materials one. The serialisation stack spans line-level printing and vision verification, site-level management, and the enterprise connections that exchange tracing data — an integration chain whose failure stops shipping even when the product itself is flawless, and whose data quality determines whether a future recall is surgical or wholesale. Artwork and labelling changes flow through change control with regulatory review, because the label is registered content: a well-made batch in a wrongly worded carton is a defective batch. Quality owns the reconciliation logic throughout — labels issued versus used versus destroyed, serial numbers commissioned versus applied versus decommissioned — because in this phase, counting is a safety control.
- Released bulk or finished product awaiting packaging, with its disposition status enforced by the inventory system.
- Approved, registered artwork and labelling for each destination market, under version control.
- A qualified packaging line, including serialisation printing, verification, and aggregation where required.
- Serial-number provisioning and data-exchange connections established with the relevant regulatory and trading-partner systems.
- Packaged units bearing correct, verified labelling and — where required — a verified unique identifier per saleable unit.
- Label and serial-number reconciliation complete within pre-defined limits, with discrepancies investigated before release.
- Container-closure integrity assured for the products whose claims depend on it.
- Serialisation event data exchanged with the required repositories and partners, so downstream verification will succeed.
- Packaging batch records complete and dispositioned, joining the product's release basis.
SPEQ synthesis. Phase boundaries and gate criteria are an organising device for planning and review, not a regulatory mandate. Real programmes overlap phases and re-enter them; treat these as the questions worth answering, not a compliance checklist.
- Own labelling control: issuance, line clearance, reconciliation, and investigation of any count that does not close.
- Approve artwork and labelling changes with regulatory verification against each market's registered text.
- Oversee the validated state of the serialisation stack — a data system whose records carry legal weight downstream.
- Set and enforce the container-closure integrity strategy for sterile and sensitive products.
- Disposition packaging batches, treating labelling and identifier discrepancies as potential market defects, not clerical noise.
- Packaging batch records with line-clearance and reconciliation evidence
- Approved artwork and labelling specifications per market
- Serialisation event data — commissioning, aggregation, shipping — exchanged per the applicable regime
- Container-closure integrity data supporting the shelf-life and sterility claims
- Serial-number and label reconciliation records
- Change-control records for artwork, components, and line configuration
- Label mix-ups from inadequate line clearance or segregation — a small-probability event whose consequence is a recall and, at worst, patient harm.
- Serialisation data mismatches — the physical unit and the exchanged record disagreeing — that surface as saleable-return or dispensing failures months later.
- Artwork changes implemented before regulatory approval lands in every affected market, putting compliant product in one country and non-compliant in another.
- Container-closure integrity assumed from the component certificate rather than demonstrated for the assembled system.
- Vision-system or printer faults handled as line engineering events without quality assessment of what shipped in the meantime.
Derived from the 5 standards SPEQ maps to this phase, across 4 regulatory bodies: FDA, EC, GS1, USP.
FREQUENTLY ASKED
Why is labelling treated as such a high-risk operation?
Because it is the one place a perfect product can become a dangerous one without anything going wrong chemically. A correct tablet in a carton naming a different strength, product, or language is a medication error waiting at the pharmacy — which is why GMP builds specific machinery around labels that exists for almost nothing else: controlled issuance against the batch, physical line clearance between runs, and reconciliation of every label issued, used, and destroyed, with unexplained discrepancies investigated before release. The controls look bureaucratic precisely because the failure mode is silent: the batch record shows a normal run either way.
What does serialisation actually require on a packaging line?
Four capabilities working as one system: generating or receiving unique serial numbers under controlled provisioning; printing the identifier and data carrier on each saleable unit; verifying — typically by camera — that what was printed is present, correct, and readable; and recording the commissioning of each number, plus aggregation to cases and pallets where the market requires it. The event data then has to reach the right counterparty: government repositories, trading partners, or both, depending on the regime. The line can be mechanically flawless and still non-compliant if the data exchange fails — the record is part of the product.
Is container-closure integrity testing a one-time validation?
No — it is a lifecycle claim. The integrity of the assembled container-closure system is established during development and validation, using the USP <1207> framework's preference for deterministic methods with measurable detection limits over probabilistic ones like dye ingress. But the claim then has to survive routine manufacture and time: component or supplier changes, line-speed and sealing-parameter drift, transport stresses, and ageing over shelf life can each degrade a seal that validated perfectly. Mature operations tie CCI into stability studies, requalify after relevant changes, and treat seal-parameter excursions as integrity events, not machine events.